Nocturia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Nocturia is defined as the need to urinate at least twice during the night. This condition becomes more common as people age and occurs in both men and women, sometimes for different reasons. Causes of nocturia include congestive heart failure, edema of lower extremities, sleeping disorders such as obstructive sleep apnea, certain drugs including diuretics, cardiac glycosides, demeclocycline, lithium, methoxyflurane, phenytoin, propoxyphene, and excessive vitamin D and drinking too much fluid before bedtime. Treatment of the condition includes anticholinergic medications.
The nocturia drugs in development market report provides an overview of the Nocturia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nocturia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nocturia and features dormant and discontinued projects.
What are the targets of the Nocturia pipeline drugs market?
The targets of the Nocturia pipeline drugs market are Vasopressin V2 Receptor, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, Vasopressin V1a Receptor, and Vasopressin V1b Receptor.
Nocturia pipeline drugs market, by targets
For more target insights, download a free report sample
What are the mechanisms of action of the Nocturia pipeline drugs market?
The mechanisms of action of the Nocturia pipeline drugs market are Vasopressin V2 Receptor Agonist, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Vasopressin V1a Receptor Agonist, and Vasopressin V1b Receptor Agonist.
Nocturia pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
What are the routes of administration in the Nocturia pipeline drugs market?
The routes of administration in the Nocturia pipeline drugs market are oral and sublingual.
Nocturia pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
What are the molecule types in the Nocturia pipeline drugs market?
The molecule types in the Nocturia pipeline drugs market are synthetic peptide, small molecule, and peptide.
Nocturia pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Which are the key companies in the Nocturia pipeline drugs market?
Some of the key companies in the Nocturia pipeline drugs market are Ferring International Center SA, Ferring Research Institute Inc, Tacurion Pharma Inc, and Wellesley Pharmaceuticals LLC.
Nocturia pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report scope
Targets | Vasopressin V2 Receptor, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, Vasopressin V1a Receptor, and Vasopressin V1b Receptor |
Mechanisms of Action | Vasopressin V2 Receptor Agonist, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Vasopressin V1a Receptor Agonist, and Vasopressin V1b Receptor Agonist |
Routes of Administration | Oral and Sublingual |
Molecule Types | Synthetic Peptide, Small Molecule, and Peptide |
Key Companies | Ferring International Center SA, Ferring Research Institute Inc, Tacurion Pharma Inc, and Wellesley Pharmaceuticals LLC |
This report provides:
- A snapshot of the global therapeutic landscape of Nocturia (Genito Urinary System and Sex Hormones).
- Reviews of pipeline therapeutics for Nocturia (Genito Urinary System and Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Key companies involved in Nocturia (Genito Urinary System and Sex Hormones) therapeutics and enlists all their major and minor projects.
- Evaluation of Nocturia (Genito Urinary System and Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Nocturia (Genito Urinary System and Sex Hormones).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Nocturia (Genito Urinary System and Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Nocturia (Genito Urinary System and Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Ferring Research Institute Inc
Tacurion Pharma Inc
Wellesley Pharmaceuticals LLC
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Nocturia pipeline drugs market?
The targets of the Nocturia pipeline drugs market are Vasopressin V2 Receptor, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, Vasopressin V1a Receptor, and Vasopressin V1b Receptor.
-
What are the mechanisms of action of the Nocturia pipeline drugs market?
The mechanisms of action of the Nocturia pipeline drugs market are Vasopressin V2 Receptor Agonist, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Vasopressin V1a Receptor Agonist, and Vasopressin V1b Receptor Agonist.
-
What are the routes of administration in the Nocturia pipeline drugs market?
The routes of administration in the Nocturia pipeline drugs market are oral and sublingual.
-
What are the molecule types in the Nocturia pipeline drugs market?
The molecule types in the Nocturia pipeline drugs market are synthetic peptide, small molecule, and peptide.
-
Which are the key companies in the Nocturia pipeline drugs market?
Some of the key companies in the Nocturia pipeline drugs market are Ferring International Center SA, Ferring Research Institute Inc, Tacurion Pharma Inc, and Wellesley Pharmaceuticals LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.